- Abzena has introduced EpiScreen 2.0, an advanced bioassay platform for evaluating immunogenicity risks in preclinical protein, antibody, and gene therapy therapeutics.
- EpiScreen 2.0 offers highly sensitive, multi-parametric, and data-rich assessments, improving candidate selection and reducing risks in early-phase development.
Abzena an end-to-end integrated CDMO for complex biologics and bioconjugates has launched EpiScreen 2.0, an enhanced bioassay platform for predicting and evaluating immunogenicity risks in preclinical protein, antibody, and gene therapy therapeutics.
The platform offers sensitive, multi-parametric, and data-rich assessments, improving candidate selection and de-risking early-phase development. Dr. Campbell Bunce, CSO of Abzena, highlighted the importance of understanding immunogenicity risks in advancing new drugs, especially with next-generation therapeutics like Antibody-drug conjugates (ADCs).
EpiScreen 2.0 uses flow cytometry and Time Course Assay to deliver sensitive measurements comparable to traditional assays, providing detailed information on specificity and mechanism-of-action (MoA) for better risk mitigation strategies. The platform supports an array of drug types including biologics, bioconjugates, and gene therapies, offering customizable methods tailored to each program’s needs.
“Understanding a lead drug candidate’s immunogenicity risk profile and how we can mitigate it is a key step in advancing new drugs from discovery to clinical trials. We developed EpiScreen 2.0 because we understand that there are many factors that contribute to the immunogenicity risk of a drug, especially with the next-generation therapeutics being developed like Antibody-drug conjugates (ADCs),” said Dr. Campbell Bunce, CSO of Abzena. “Our EpiScreen 2.0 platform allows drug developers to be better informed and more confident in progressing to later stage development with a better chance of success in patients.”
Overview of outsourcing trends 
